Leucine-rich α-2 glycoprotein 1 (LRG1) during inflammatory complications after allogeneic stem cell transplantation and CAR-T cell therapy
The current data support the hypothesis that LRG1 is an attractive therapeutic target after alloHSCT and after CAR-T cell therapy for cancer because of its role in dysfunctional tumor vessels as well as in inflammatory complications.
Authors
- Katarina Riesner (ORCID: https://orcid.org/0000-0001-5745-8184)
- John Pierre Greenwood (ORCID: https://orcid.org/0000-0002-2861-0914)
- Hadeer Mohamed Rasheed (ORCID: https://orcid.org/0000-0003-1010-296X)
- Lars Bullinger (ORCID: https://orcid.org/0000-0002-5890-5510)
- Ningyu Li (ORCID: https://orcid.org/0000-0003-2416-992X)
- Pedro Vallecillo-García (ORCID: https://orcid.org/0000-0001-6833-5972)
- Jerome Jatzlau (ORCID: https://orcid.org/0000-0002-1757-0267)
- Martina Kalupa
- Stephen E. Moss (ORCID: https://orcid.org/0000-0002-7304-8879)
- Olaf Penack (ORCID: https://orcid.org/0000-0003-4876-802X)
- Petra Knaus (ORCID: https://orcid.org/0000-0003-2492-1667)
- Sarah Mertlitz (ORCID: https://orcid.org/0000-0002-7245-5616)
- Lydia Verlaat
- Steffen Cordes
- Mina Jamali
- Nora Uhlig
Institutions
- Humboldt-Universität zu Berlin (DE)
- National Center for Tumor Diseases (DE)
- German Marine Research Consortium (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- University College London (GB)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/jitc-2024-009372
- Citations
- 1
- Primary Topic
- Clusterin in disease pathology
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Deutsche Forschungsgemeinschaft
- José Carreras Leukämie-Stiftung
- Deutsche Krebshilfe
- Stiftung Charité